CN119136785A - 包含溶解的缓激肽b2受体拮抗剂的固体组合物 - Google Patents
包含溶解的缓激肽b2受体拮抗剂的固体组合物 Download PDFInfo
- Publication number
- CN119136785A CN119136785A CN202380037794.6A CN202380037794A CN119136785A CN 119136785 A CN119136785 A CN 119136785A CN 202380037794 A CN202380037794 A CN 202380037794A CN 119136785 A CN119136785 A CN 119136785A
- Authority
- CN
- China
- Prior art keywords
- disorders
- solid dispersion
- diseases
- receptor antagonist
- sustained release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22164462.8 | 2022-03-25 | ||
| EP22164462 | 2022-03-25 | ||
| PCT/EP2023/057791 WO2023180575A1 (en) | 2022-03-25 | 2023-03-27 | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119136785A true CN119136785A (zh) | 2024-12-13 |
Family
ID=80952146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380037794.6A Pending CN119136785A (zh) | 2022-03-25 | 2023-03-27 | 包含溶解的缓激肽b2受体拮抗剂的固体组合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250228781A1 (enExample) |
| EP (1) | EP4499038B1 (enExample) |
| JP (1) | JP2025512818A (enExample) |
| KR (1) | KR20240161689A (enExample) |
| CN (1) | CN119136785A (enExample) |
| AU (1) | AU2023241243A1 (enExample) |
| CA (1) | CA3250835A1 (enExample) |
| CO (1) | CO2024012879A2 (enExample) |
| ES (1) | ES3062067T3 (enExample) |
| HR (1) | HRP20260166T1 (enExample) |
| IL (1) | IL315699A (enExample) |
| MA (1) | MA69209B1 (enExample) |
| MX (1) | MX2024011703A (enExample) |
| PL (1) | PL4499038T3 (enExample) |
| WO (1) | WO2023180575A1 (enExample) |
| ZA (1) | ZA202408058B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102824038B1 (ko) | 2025-01-20 | 2025-06-23 | 송재혁 | 차량 종합 검사 시스템 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1168667A (zh) | 1994-10-27 | 1997-12-24 | 藤沢药品工业株式会社 | 用作缓激肽拮抗剂的吡啶并嘧啶酮，喹啉和稠合的n-杂环化合物 |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| EP1085895A1 (en) | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Bradykinin antagonists |
| EP1123288A1 (en) | 1998-10-21 | 2001-08-16 | Fujisawa Pharmaceutical Co., Ltd. | Vitreous form of known bradykinin antagonist |
| FR2790260B1 (fr) | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| JP2005525398A (ja) | 2002-04-10 | 2005-08-25 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体 |
| ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| KR20150127718A (ko) | 2013-03-14 | 2015-11-17 | 샤이어 휴먼 지네틱 테라피즈 인크. | Ｂ2-브라디키닌 수용체 매개 혈관부종의 치료 방법 |
| SMT202200154T1 (it) | 2017-11-24 | 2022-05-12 | Pharvaris Netherlands B V | Nuovi antagonisti del recettore della bradichinina b2 |
| AR118983A1 (es) * | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| CA3198246A1 (en) * | 2020-11-12 | 2022-05-19 | Pharvaris Gmbh | Prophylaxis and treatment of angioedema |
-
2023
- 2023-03-27 HR HRP20260166TT patent/HRP20260166T1/hr unknown
- 2023-03-27 AU AU2023241243A patent/AU2023241243A1/en active Pending
- 2023-03-27 CA CA3250835A patent/CA3250835A1/en active Pending
- 2023-03-27 PL PL23715487.7T patent/PL4499038T3/pl unknown
- 2023-03-27 US US18/850,679 patent/US20250228781A1/en active Pending
- 2023-03-27 EP EP23715487.7A patent/EP4499038B1/en active Active
- 2023-03-27 WO PCT/EP2023/057791 patent/WO2023180575A1/en not_active Ceased
- 2023-03-27 ES ES23715487T patent/ES3062067T3/es active Active
- 2023-03-27 IL IL315699A patent/IL315699A/en unknown
- 2023-03-27 KR KR1020247035351A patent/KR20240161689A/ko active Pending
- 2023-03-27 JP JP2024556786A patent/JP2025512818A/ja active Pending
- 2023-03-27 MA MA69209A patent/MA69209B1/fr unknown
- 2023-03-27 CN CN202380037794.6A patent/CN119136785A/zh active Pending
-
2024
- 2024-09-24 CO CONC2024/0012879A patent/CO2024012879A2/es unknown
- 2024-09-24 MX MX2024011703A patent/MX2024011703A/es unknown
- 2024-10-24 ZA ZA2024/08058A patent/ZA202408058B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4499038A1 (en) | 2025-02-05 |
| PL4499038T3 (pl) | 2026-04-27 |
| JP2025512818A (ja) | 2025-04-22 |
| IL315699A (en) | 2024-11-01 |
| EP4499038B1 (en) | 2025-12-03 |
| MX2024011703A (es) | 2024-11-08 |
| AU2023241243A1 (en) | 2024-11-07 |
| CA3250835A1 (en) | 2023-09-28 |
| KR20240161689A (ko) | 2024-11-12 |
| ZA202408058B (en) | 2026-01-28 |
| EP4499038C0 (en) | 2025-12-03 |
| HRP20260166T1 (hr) | 2026-03-27 |
| WO2023180575A1 (en) | 2023-09-28 |
| US20250228781A1 (en) | 2025-07-17 |
| MA69209B1 (fr) | 2026-03-31 |
| ES3062067T3 (en) | 2026-04-08 |
| CO2024012879A2 (es) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101737250B1 (ko) | 개선된 생체이용률을 갖는 약학 조성물 | |
| JP5017115B2 (ja) | ４−（４−（３−（４−クロロ−３−トリフルオロメチルフェニル）ウレイド）−３−フルオロフェノキシ）ピリジン−２−カルボン酸を含んでなる過剰増殖性疾患の治療のための新規薬剤組成物 | |
| CN101636152B (zh) | 含有西洛他唑的控释制剂及其制备方法 | |
| AU2010323097B2 (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| AU2016364976B2 (en) | Solid dispersions comprising a sGC stimulator | |
| AU2016263338B2 (en) | SOMCL-9112 solid dispersion and preparation method thereof and SOMCL-9112 solid preparation containing SOMCL-9112 solid dispersion | |
| CA2624306A1 (en) | Solid pharmaceutical dosage forms which can be adminstered orally and have rapid release of active ingredient | |
| TW201924688A (zh) | 固體分散體 | |
| EP4499038B1 (en) | Solid composition comprising solubilised bradykinin b2-receptor antagonists | |
| EP4499039B1 (en) | Solid extended-release composition comprising bradykinin b2-receptor antagonists | |
| US20250268887A1 (en) | Therapeutic uses of bradykinin b2-receptor antagonists | |
| EA052832B1 (ru) | Твердая композиция с пролонгированным высвобождением, содержащая антагонисты брадикининовых в2-рецепторов | |
| CN105726499B (zh) | 一种利伐沙班药物组合物及其制备方法 | |
| CN120076794A (zh) | 包含纳波拉非尼的无定形固体分散体 | |
| CN117956993A (zh) | 索拉非尼的无定形固体分散体和包含其的固体制剂 | |
| CN117695279A (zh) | 氯雷他定组合物及氯雷他定药物 | |
| HK40045939A (en) | Pharmaceutical composition with improved bioavailability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |